Effective Treatments for Methamphetamine Use Disorder: A Review

Methamphetamine (MA) use disorder represents a significant public health challenge, characterized by rising mortality rates and a high proportion of individuals seeking repeat treatment. Because no pharmacotherapeutic agents have been proven robustly effective in clinical trials, the clinical burden for treatment falls primarily on behavioral and psychosocial interventions. This review synthesizes existing research on both pharmacotherapy and psychosocial models, evaluating their efficacy in reducing MA use and improving recovery outcomes.

A wide range of medications, including antidepressants (e.g., mirtazapine, bupropion), antipsychotics, and substitution therapies, have been investigated for MA dependence. Despite these efforts, no drug has achieved FDA approval for this condition. Systematic reviews consistently report that current pharmaceutical candidates lack sufficient evidence to demonstrate a robust, sustained treatment effect. While some agents show promise for specific subgroups or comorbid conditions, clinical data generally do not support their use as standalone treatments for MA dependence.

Psychosocial approaches remain the mainstay of treatment. These interventions generally aim to increase treatment engagement, build coping skills, and minimize harm. The review highlights several key approaches:

• Matrix Model (MM): An intensive, manualized outpatient program combining cognitive-behavioral therapy (CBT), family education, and social support. It is widely used and has demonstrated improved retention and abstinence during treatment compared to standard care, though long-term benefits beyond the treatment period are less clear.
• Cognitive-Behavioral Therapy (CBT): Programs focused on relapse prevention and skill acquisition show modest efficacy, though brief or web-based adaptations have yielded inconsistent results.
• Contingency Management (CM): This approach uses positive reinforcement (e.g., vouchers) to reward abstinence or treatment compliance. It is arguably the most promising psychosocial tool for increasing short-term abstinence, yet its effectiveness often wanes once incentives are removed, and the model is frequently cited as cost-prohibitive or difficult to implement in real-world settings.
• Lifestyle Interventions: Emerging research suggests that exercise programs and mindfulness-based relapse prevention may reduce comorbid symptoms like depression and anxiety, potentially aiding the recovery process.